Evaluation of Pyroptosis-related Indicators in the Pathogenesis of Vitiligo:Across-sectional Comparative Study

Sohag University

Status: Not yet enrolling

Conditions: Vitiligo

Treatments: Diagnostic Test: evaluate serum levels pyroptosis-related indicators (GASDM-D, IL 1β & IL-18)

Study type: Interventional

Funder types: Other

Identifiers

NCT06261086

soh-med-24-01-06MS

Details and patient eligibility

About

Vitiligo is an acquired pigmentary disorder on skin and/or mucosae, which is characterized by death of melanocytes (MCs), affecting 0.5%-2% of the population worldwide (1). It doesn't affect the health of patients but it has marked social pressure and greatly interfere with their quality of life (2,3). It presents with well circumscribed milky white patches that occur secondary to destruction of melanocyte, it may appear at any age and affect both sexes equally.

It can affect ethnic groups and people of all skin types with no predilection (4).

Clinically, several types of vitiligo are distinguished according to the distribution of the achromic lesions. One or more lesions in a dermatomal pattern are characteristic for segmental vitiligo (SV) while this segmental distribution is absent in non-segmental vitiligo (NSV). The latter variety includes both the focal type and the generalized type (5). Numerous previous studies tried to illustrate the pathogenesis behind the disease, but the exact pathophysiology is still not fully understood. It is a multifactorial disease. Factors include, neural theory, oxidative stress theory, autoimmune hypothesis, intrinsic theory, melanocytorrhagy hypothesis (6). Many theories tried to explain the mechanisms of MC destruction in vitiligo. Apoptosis is one of the most widely studied cell death pathways. In addition, the other two forms of cell death, conventional necrosis and autophagy seem to be involved in the death of vitiligo MCs under certain situations. Moreover, new types of regulated cell death including necroptosis, pyroptosis, and ferroptosis may also participate in the pathogenesis (7). Pyroptosis is a highly inflammatory form of necrosis cell death NCD regulated mainly by caspase-1, which is initiated following large supramolecular complex ermed inflammasome activation (8). The inflammasome-activated Caspases then cleave the pyroptosis-inducing protein Gasdermin D (GSDMD), which forms a pore in the plasma membrane and causes cell lysis as well as the secretion of IL-1β typically (9). Another study suggests that inflammasome activation could be a useful marker for assessing disease progression of vitiligo (10). However, the link between vitiligo and inflammasome activation is still unclear. The inflammasome regulates cell death and inflammation via activation of caspase-1 (11). The activation of caspase-1 promotes the secretion of proinflammatory cytokines IL-1β and IL-18, as well as the initiation of pyroptosis (12). So, evaluation of pyroptosis-related indicators (GASDM-D, IL 1β & IL-18) may help understanding the obscure inflammasome pathway involvement in the pathogenesis of Vitiligo.

Enrollment: 90 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients with vitiligo ≥ 18 years old, both male and female patients will be included.

Exclusion criteria

• Patients with the following criteria will be excluded from our study:

  1. Pregnancy and breast-feeding women
  2. patients on antioxidants or anti-inflammatory drugs
  3. Patients on topical/systemic treatment for vitiligo in the last 4weeks prior to enrollment in the study
  4. Patients with other dermatological diseases as psoriasis, lichen planus, viral infection, etc.
  5. Patients suffering from chronic medical illness such as; diabetes mellitus, thyroid disease, and cancer.

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

90 participants in 2 patient groups

patient with vitiligo group

Active Comparator group

Description:

Patients with vitiligo ≥ 18 years old, both male and female patients will be included. Exclusion criteria: Patients with the following criteria will be excluded from our study: 1. Pregnancy and breast-feeding women. 2. patients on antioxidants or anti-inflammatory drugs 3. Patients on topical/systemic treatment for vitiligo in the last 4weeks prior to enrollment in the study 4. Patients with other dermatological diseases as psoriasis, lichen planus, viral infection, etc. 5. Patients suffering from chronic medical illness such as; diabetes mellitus, thyroid disease, and cancer.

Treatment:

Diagnostic Test: evaluate serum levels pyroptosis-related indicators (GASDM-D, IL 1β & IL-18)

control group

Active Comparator group

Description:

control criteria with the following criteria will be excluded from our study: 1- Pregnancy and breast-feeding women.

Treatment:

Diagnostic Test: evaluate serum levels pyroptosis-related indicators (GASDM-D, IL 1β & IL-18)